LL-37

Also known as: Human Cathelicidin

ImmunePHASE 1

Clinical Status

Investigational — clinical trials for wound healing.

Mechanism of Action

Directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. Also modulates the immune response and has anti-biofilm activity.

Dosing Defaults

Dose

100-200 mcg

Frequency

1x daily

Administration

Subcutaneous injection or topical

Timing

Morning

Food

with or without

Duration

Variable by protocol

Dose range: 50-300 mcg daily

Morning dosing supports immune function during active hours.

Side Effects

•Injection site reactions
•Skin toxicity at high doses
•Allergic reactions
•May trigger histamine release

Contraindications & Warnings

•Not medical advice
•Limited long-term safety data

Compare

Compare LL-37 with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your LL-37 dose.

Open Calculator

Related Immune Peptides

KPV

PRECLINICAL

Immune

Anti-inflammatory peptide fragment. Does NOT cause immunosuppression.

Thymosin Alpha-1

PHASE 3

Immune

Thymic peptide for immune modulation. Approved in 35+ countries.

VIP

PHASE 2

Immune

Immunomodulatory peptide used in mold illness (CIRS) protocols.

Thymulin

PRECLINICAL

Immune

Zinc-dependent thymic peptide that promotes T-cell maturation and immune balance.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.